FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

l	OMB APPRO	IVAL
	OMB Number:	3235-0287
l	Estimated average burd	en
l	hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* MUELLER PETER					<u>V</u>	2. Issuer Name and Ticker or Trading Symbol VERTEX PHARMACEUTICALS INC / MA [VRTX]								5. Relationship of Re (Check all applicable Director			g Pers	10% Ov	/ner
INCORP	Last) (First) (Middle) C/O VERTEX PHARMACEUTICALS INCORPORATED 130 WAVERLY STREET				12/	3. Date of Earliest Transaction (Month/Day/Year) 12/04/2009								X Officer (give title below) Other (specify below) EVP Global R&D, CSO					
(Street) CAMBRIDGE MA 02139				- 4. l' -	4. If Amendment, Date of Original Filed (Month/Day/Year)								Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person						
(City)	(Si		(Zip)																
Table I - Non-Deriva 1. Title of Security (Instr. 3) 2. Transactio Date (Month/Day/N			tion	n 2A. Deemed Execution Date,		3. Transaction Code (Instr.		4. Securities	sed of, or Benefic ecurities Acquired (A) or osed Of (D) (Instr. 3, 4 an			5. Amou Securition Benefici Owned I	int of es ially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership			
									Code	v	Amount	(A) or (D)	Price	- 1	Reporte Transac (Instr. 3	tion(s)			Instr. 4)
Common Stock 12/04/20			2009				М		1,600	A	\$10.41		118	3,474		D			
Common Stock 12/04/200			2009	09		S ⁽¹⁾		1,600	D	\$39.62(2	52 ⁽²⁾⁽³⁾		116,874		D				
Common Stock								3,882			I	401(k)							
		Т	able I								posed of , converti			/ Ov	vned				
Derivative Conversion Date Escurity Or Exercise (Month/Day/Year) if		Execut if any			ransaction ode (Instr.		umber vative urities uired or oosed O) tr. 3, 4	6. Date Exerc Expiration Da (Month/Day/Y		ate	7. Title a Amount Securitie Underlyi Derivativ (Instr. 3	of es ng /e Security	Der Sec	Price of erivative ecurity nstr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	e (10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares						
Stock Option	\$10.41	12/04/2009			M			1,600	(4)		02/02/2015	Commor	1,600		\$0	34,400		D	

Explanation of Responses:

- 1. Transaction made pursuant to Dr. Mueller's company approved trading plan under Rule 10b5-1.
- $2. Open \ market \ sales \ reported \ on \ this \ line \ occurred \ at \ a \ weighted \ average \ price \ of \ \$39.62 \ (range \ \$39.29 \ to \ \$40.24).$
- 3. Dr. Mueller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- 4. Fully vested.

Remarks:

Kenneth S. Boger, Attorney-In-12/09/2009

Fact

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.